Quote:

---

The 30-patient clinical trial, dubbed NCT04261517, was in mild patients, and open-label. However, it was randomized (unlike many other Chinese trials), and specifically investigated hydroxychloroquine (400mg/day) against placebo in Covid-19 patients with pneumonia, he said.

---

Quote:

---

The main goal of the study — virological clearance rate — was higher on the placebo arm at 93%, versus 87% on the hydroxychloroquine cohort. Temperature normalization was essentially the same — 1 day in both groups. Radiological progression on CT images favored hydroxychloroquine — 33% on the drug arm, compared to 47% in the control group — but these data are hard to interpret since there were just 5 versus 7 cases that progressed, Raffat cautioned.

---